Spyre Therapeutics, Inc.
SYRE
$103.63
$1.781.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 8.43% | 35.34% | |||
| Gross Profit | -8.43% | -35.34% | |||
| SG&A Expenses | 5.95% | 21.51% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.93% | 32.30% | |||
| Operating Income | -7.93% | -32.30% | |||
| Income Before Tax | 47.54% | -10.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 47.54% | -10.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 47.54% | -10.36% | |||
| EBIT | -7.93% | -32.30% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 50.78% | -7.42% | |||
| Normalized Basic EPS | 28.65% | -51.35% | |||
| EPS Diluted | 50.78% | -7.42% | |||
| Normalized Diluted EPS | 28.65% | -51.35% | |||
| Average Basic Shares Outstanding | 7.87% | 4.61% | |||
| Average Diluted Shares Outstanding | 7.87% | 4.61% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||